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ABSTRACT
This is a remarkable progress; since the finding of statins, there was 
no new way of reducing, significantly, cholesterol and LDL fraction. 
It is also clear that this decrease, by statins, is related to future 
cardiovascular lesions, being useful in its primary and secondary 
prophylaxis. The authors presented studies on research to promote 
the falling of blood cholesterol by means of antibodies, which inhibit 
the pro-protein PCSK9, as well as agents that act performing the RNA 
interference. We had two advantages immediately: for patients with 
myopathy associated with statins, and the fact of being injected 
every 15 days, that may contribute to better treatment adherence.
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RESUMO
Este é um progresso sensível; desde a descoberta das estatinas, 
não havia novas maneiras de diminuir, de maneira significativa, o 
colesterol e a fração LDL. Também está claro que essa redução, pelas 
estatinas, tem relação com futuras lesões cardiovasculares, sendo útil 
na profilaxia primária e secundária destas. Os autores apresentaram 
estudos sobre pesquisas para promover a queda do colesterol sanguíneo 
por meio de anticorpos que inibem a pró-proteína PCSK9, bem 
como agentes que atuam realizando a interferência no RNA. Duas 
vantagens se afiguram imediatamente: para pacientes que têm a 
miopatia relacionada às estatinas e por ser droga injetável a cada 15 
dias, o que pode colaborar para maior adesão ao tratamento.
Descritores: Dislipidemias; Lipoproteínas; LDL-colesterol
INTRODUCTION
The proprotein convertase subtilisin/kexin type 9, also 
known as PCSK9, is an enzyme that is encoded by 
gene PCSK9(1) in humans, and has orthologous genes 
found in virtually all species. This gene encodes a 
proprotein convertase from the proteinase K subfamily, 
of the secretory subtilase family. The encoded protein 
is synthesized as a soluble zymogen, which undergoes 
an intramolecular self-catalytic processing in the 
endoplasmic reticulum. This protein plays an essential 
role in regulation of cholesterol homeostasis. PCSK9 
binds to the repetition domain A, of the epidermal 
growth factor (EGF-A), to the low-density lipoprotein 
receptor (R-LDL), inducing degradation of this receptor. 
These reduced R-LDL levels result in decreased 
metabolism of low-density lipoproteins (LDL-cholesterol 
- LDL-c), which could lead to hypercholesterolemia(2,3).
CLINICAL RELEVANCE 
Inhibiting function of PCSK9 is explored as a way to 
reduce cholesterol levels. Research has advanced in 
studying antibodies against this enzyme, aiming at its 
inhibition. It is worth mentioning that the use of statins 
is well established in clinical practice. Statins interfere 
in cholesterol production by inhibiting the enzyme 
HMG-CoA reductase(4) and stimulating the production 
of LDL receptors; meanwhile, these antibodies allow 
more LDL receptors to be available(5). 
Currently, four different therapeutic targets against 
PCSK9 are under investigation; in that, Ac anti-PCSK9 
– REGN727/SAR236553 (Regeneron Pharmaceuticals/
Sanofi) has more data available(6).
The most recent phase II study was published 
online on October 31, 2012, in the New England Journal 
of Medicine, and was carried out by a tem led by 
Dr. Eli Roth. The project involved 92 patients, with 
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LDL levels ≥100mg/dL after receiving atorvastatin 
10 mg for at least 7 weeks. They were randomized 
for 8-week treatment, at the ratio of 1:1:1 – receiving 
atorvastatin 80mg/day + REGN727/SAR236553; 
atorvastatin 10mg/day + REGN727/SAR236553 and 
atorvastatin 80mg/day + placebo. The drug REGN727/
SAR236553 was administered every two weeks, 
subcutaneously. The exclusion criteria included type-1 
diabetes mellitus, uncontrolled type-2 diabetes mellitus 
(glycated hemoglobin >8.5%) or on insulin, triglycerides 
>350mg/dL or any cardiovascular events in the past 6 
months before the study. The results on the monoclonal 
antibody anti-PCSK9 REGN727/SAR236553 showed 
important reduction in LDL levels, in both associations 
(atorvastatin 10mg and 80mg) in patients with primary 
dyslipidemia (Table 1). In the placebo group, the drop 
was by 2.7% only. Like in previous studies with the 
same therapy, there was a decrease by approximately 
one-third lipoprotein-a Lp (a) levels in patients who 
received the antibody(7).
The Odyssey study with this antibody is on its 
phase III since July 2012. A total of 22000 patients 
will be enrolled, distributed throughout 2000 centers 
all over the world (United States, Europe, Canada, 
Australia, Asia and South America, including Brazil). 
It is conducted by Professor Dr Henry Ginsberg, of the 
Columbia University Medical Center, in New York.
Another way to inhibit the action of PCSK9 would 
be to use the therapeutic targets that act interfering 
in RNA, that is, RNA interference (RNAi)(8). The 
RNAi is a great advance in medicine, and represents 
understanding of how genes are switched on and off 
in the cells, and provides a totally new approach to 
discovery and development of new medications. Its 
discovery was announced as “a great scientific advance 
that occurs once in every ten or more years” and it 
represents one of the most promising findings, being 
awarded the Nobel Prize of Physiology, in 2006(9,10). 
Alnylam Pharmaceuticals recently demonstrated in 
initial clinical trials (Phase 1), the positive results of the 
new drug ALN-PCS, which has the same action, and 
effectively inhibits this proprotein.
New studies will be published soon, enabling a better 
evaluation of these promising therapeutic targets.
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Table 1. Reductions in LDL-cholesterol in patients with primary dyslipidemia
Groups
Reduction in LDL 
levels from baseline 
(%)
p value  
(versus atorvastatin 
80mg + placebo)
Atorvastatin 80mg + antibody 73.2 <0.001
Atorvastatin 10mg + antibody 66.2 <0.001
Atorvastatin 80mg + placebo 17.3 —
